Evidence map›Paper›PMID 31912436›Full record

ReviewJournal of nephrology2020

The renal adverse effects of cancer immunotherapy.

Natalie C Steinel, Ernestine M Lee, Davide Viggiano, Anna Capasso, Michael W Lee

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Natalie C SteinelDepartment of Biological Sciences, University of Massachusetts Lowell, Lowell, MA, USA.
Ernestine M LeeDepartment of Population Health, Division of Family Medicine, Dell Medical School, University of Texas At Austin, Austin, TX, USA.
Davide ViggianoDepartment of Translational Medical Sciences, University Luigi Vanvitelli, Naples, Italy.
Anna CapassoDepartment of Oncology, Dell Medical School, The University of Texas at Austin, Health Learning Building, 1501 Red River Street, MC: Z0100, Austin, TX, 78712, USA.
Michael W LeeDepartment of Oncology, Dell Medical School, The University of Texas at Austin, Health Learning Building, 1501 Red River Street, MC: Z0100, Austin, TX, 78712, USA. Lee_Michael@austin.utexas.edu.ORCID http://orcid.org/0000-0001-8954-2057
Livestrong Foundation · USThe University of Texas at Austin · USUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Massachusetts Lowell · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past decade, the development and clinical use of immunotherapy agents has increased exponentially. As clinical experience builds with these agents so too does our understanding of the associated adverse effects. In particular, the effects of immunotherapy on the kidneys, individual nephrons, and kidney function remain less well described than the adverse effects on barrier organ systems such as the gastrointestinal tract and skin. However, phase IV post-marketing surveillance and clinical case studies together with basic research has begun to reveal mechanisms by which immunotherapy mediates renal adverse effects. This work may lead to improvements in treatment guidelines and therapy. These advances are particularly important as post-cancer survival increases leaving patients to cope with the consequences of not only the cancer, but the short- and long-term adverse effects of treatment. Here we discuss the major renal adverse effects encountered with individual immunotherapeutic agents, putative mechanisms, their current management, and how cancer survivorship programs can help patients who have been treated with immunotherapy.

Indexed as

ImmunotherapyNeoplasmsHumansKidneyImmunotherapyMonoclonal antibodiesRenal adverse effectsSurvivorship

Identifiers

PMID31912436
OpenAlexW2999835534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.